These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12050019)

  • 1. Iron chelators as therapeutic agents for the treatment of cancer.
    Richardson DR
    Crit Rev Oncol Hematol; 2002 Jun; 42(3):267-81. PubMed ID: 12050019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
    Lovejoy DB; Richardson DR
    Curr Med Chem; 2003 Jun; 10(12):1035-49. PubMed ID: 12678675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of iron chelation in cancer therapy.
    Buss JL; Torti FM; Torti SV
    Curr Med Chem; 2003 Jun; 10(12):1021-34. PubMed ID: 12678674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR; Milnes K
    Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelators in cancer chemotherapy.
    Buss JL; Greene BT; Turner J; Torti FM; Torti SV
    Curr Top Med Chem; 2004; 4(15):1623-35. PubMed ID: 15579100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelators for the treatment of cancer.
    Yu Y; Gutierrez E; Kovacevic Z; Saletta F; Obeidy P; Suryo Rahmanto Y; Richardson DR
    Curr Med Chem; 2012; 19(17):2689-702. PubMed ID: 22455580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.
    Lovejoy DB; Richardson DR
    Blood; 2002 Jul; 100(2):666-76. PubMed ID: 12091363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity.
    Kovacevic Z; Kalinowski DS; Lovejoy DB; Quach P; Wong J; Richardson DR
    Curr Drug Deliv; 2010 Jul; 7(3):194-207. PubMed ID: 20507267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E; Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
    Serda M; Kalinowski DS; Mrozek-Wilczkiewicz A; Musiol R; Szurko A; Ratuszna A; Pantarat N; Kovacevic Z; Merlot AM; Richardson DR; Polanski J
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5527-31. PubMed ID: 22858101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The medicinal chemistry of novel iron chelators for the treatment of cancer.
    Kovacevic Z; Kalinowski DS; Lovejoy DB; Yu Y; Suryo Rahmanto Y; Sharpe PC; Bernhardt PV; Richardson DR
    Curr Top Med Chem; 2011; 11(5):483-99. PubMed ID: 21192781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of iron chelators in cancer therapy.
    Richardson DR
    Adv Exp Med Biol; 2002; 509():231-49. PubMed ID: 12572997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites.
    Walcourt A; Loyevsky M; Lovejoy DB; Gordeuk VR; Richardson DR
    Int J Biochem Cell Biol; 2004 Mar; 36(3):401-7. PubMed ID: 14687919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.
    Richardson DR
    Leuk Lymphoma; 1998 Sep; 31(1-2):47-60. PubMed ID: 9720714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
    Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
    Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel chelators for cancer treatment: where are we now?
    Merlot AM; Kalinowski DS; Richardson DR
    Antioxid Redox Signal; 2013 Mar; 18(8):973-1006. PubMed ID: 22424293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelator research: past, present, and future.
    Tam TF; Leung-Toung R; Li W; Wang Y; Karimian K; Spino M
    Curr Med Chem; 2003 Jun; 10(12):983-95. PubMed ID: 12678671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.